Jade Biosciences develops antibody medicines for autoimmune diseases, starting with a candidate for the kidney disease IgA nephropathy. It last closed at $15.31 on Nov 20, up 1.66% on the day. The next earnings report for JBIO is expected around Fri, Mar 5, 2027. For the quarter ended Sep 2026, JBIO reported EPS of -$0.42. Over its last 8 reports the stock moved an average of 7.6% the session after earnings.
AI Auto Pilots
Is JBIO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold JBIO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on JBIOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
JBIO · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend
The stock is 1% above its 20 day and 2% above its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 51). The nearest support is the Pivot at $15.28, and the nearest resistance the swing high (Oct 22) at $15.44.
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 6.4%/day
Key levels
$28.0052 week high+82.9%
$18.21200 day average+18.9%
$18.03100 day average+17.8%
$15.57Pivot R1+1.7%
$15.44Swing high (Oct 22)+0.8%
$15.31Last close
$15.28Pivot−0.2%
$15.1020 day average−1.4%
$15.03Pivot S1−1.8%
$14.9550 day average−2.4%
$14.60Swing low (Nov 17)−4.6%
$11.0252 week low−28.0%
Indicators
RSI (14)
50.70
Middle of its range
Neutral
MACD
0.13
Above its signal line
Bullish
Stochastic
47.6
Middle of its range
Neutral
ADX (14)
18.5
No clear trend
Williams %R
-52.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
18.6
Oversold below −100, overbought above 100
Neutral
Rate of change
+1.6%
Change over 10 sessions
Bullish
ATR (14)
$0.98
Typical daily range, 6.4% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 16.4%/day
Key levels
$28.0052 week high+82.9%
$18.21200 day average+18.9%
$18.03100 day average+17.8%
$15.57Pivot R1+1.7%
$15.44Swing high (Oct 22)+0.8%
$15.31Last close
$15.28Pivot−0.2%
$15.1020 day average−1.4%
$15.03Pivot S1−1.8%
$14.9550 day average−2.4%
$14.60Swing low (Nov 17)−4.6%
$11.0252 week low−28.0%
Indicators
RSI (14)
44.69
Middle of its range
Neutral
MACD
-1.04
Below its signal line
Bearish
Stochastic
21.9
Middle of its range
Neutral
ADX (14)
19.5
No clear trend
Williams %R
-79.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
-56.4
Oversold below −100, overbought above 100
Neutral
Rate of change
−14.4%
Change over 10 sessions
Bearish
ATR (14)
$2.51
Typical daily range, 16.4% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for JBIO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how JBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow JBIO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for JBIOHow many large options trades hit JBIO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in JBIO in the last 90 days.
From SEC Form 4 filings by JBIO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JBIO is in one of them and how their past JBIO trades turned out.
Jade Biosciences is a biopharmaceutical company based in Waltham, Massachusetts, that is developing antibody medicines for people with autoimmune diseases. Its main candidate, JADE101, targets a signaling protein called APRIL and is being developed first for IgA nephropathy, a progressive kidney disease. The company is also developing JADE201, which targets the BAFF receptor on B cells, for several autoimmune disorders. Its products are still in clinical trials and are not yet sold to patients.